Market Overview

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Share:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
Related IBB
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates
The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal
If The Market Gives You Bad Dreams, Time To Get Up (TalkMarkets)
Related PFE
October's biggest Losers And Most Surprising Winners
Tariffs, Drug Prices, Legislative Gridlock: What Economists Are Watching Following The Midterm Election
Cancer Research Highlight: AstraZeneca Finally Fulfills The Premonitions Of Ill Fate In NSCLC (Seeking Alpha)

Biotech stocks saw modest gains this week, with earnings providing a boost even as clinical trial results elicited a mixed reaction.

Eli Lilly And Co (NYSE: LLY), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Gilead Sciences, Inc. (NASDAQ: GILD) are among some prominent biotechs that reported solid results and offered optimistic assessments for thenear-to-medium term. 

Looking ahead to the upcoming week, biotech investors should watch for the following catalytic events. 

Conferences

  • Global Experts Meeting On Diabetes, Hypertension & Metabolic Syndrome: July 30-31 in Melbourne, Australia.
  • 8th International Conference on Geriatrics Gerontology & Palliative Nursing: July 30-31 in Barcelona, Spain.
  • International Pan Pacific Conference of ART & Perinatology: Aug. 3-5 in Las Vegas.

PDUFA Dates

FDA is set to announce its verdict on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)'s rare neuroendocrine tumor treatment candidate Azedra on Sunday, July 30.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and AbbVie Inc (NYSE: ABBV) await the FDA's ruling on Elagolix for endometriosis-associated pain. Based on the three-month extension in the review period announced by the FDA on April 10, the decision could come in July or early August.

See Also: Tricida Post-IPO Run-up Makes Goldman Wary

Earnings

Monday

  • Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close)
  • GenMark Diagnostics, Inc (NASDAQ: GNMK) (after the close)
  • Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the open)

Tuesday

  • Pulse Biosciences Inc (NASDAQ: PLSE) (after the close)
  • Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the close)
  • NewLink Genetics Corp (NASDAQ: NLNK) (after the close)
  • Incyte Corporation (NASDAQ: INCY) (before the open)
  • Medpace Holdings Inc (NASDAQ: MEDP) (before the open)
  • Hologic, Inc. (NASDAQ: HOLX) (after the close)
  • Pfizer Inc. (NYSE: PFE) (before the open)
  • NuVasive, Inc. (NASDAQ: NUVA) (after the close)
  • Qiagen NV (NYSE: QGEN)
  • Illumina, Inc. (NASDAQ: ILMN) (after the close)

Wednesday

  • Conatus Pharmaceuticals Inc (NASDAQ: CNAT) (after the close)
  • Amarin Corporation plc (ADR) (NASDAQ: AMRN) (before the open)
  • ArQule, Inc. (NASDAQ: ARQL) (before the open)
  • AtriCure Inc. (NASDAQ: ATRC) (after the close)
  • AxoGen, Inc (NASDAQ: AXGN)
  • Blueprint Medicines Corp (NASDAQ: BPMC) (before the open)
  • EXACT Sciences Corporation (NASDAQ: EXAS) (after the close)
  • Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the close)
  • Globus Medical Inc (NYSE: GMED) (after the close)
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX) (before the open)
  • Clovis Oncology Inc (NASDAQ: CLVS) (after the close)
  • DURECT Corporation (NASDAQ: DRRX) (after the close)
  • Exelixis, Inc. (NASDAQ: EXEL) (after the close)

Thursday

  • Genomic Health, Inc. (NASDAQ: GHDX) (after the close)
  • Obalon Therapeutics Inc (NASDAQ: OBLN) (before the open)
  • Acceleron Pharma Inc (NASDAQ: XLRN) (after the close)
  • Insmed Incorporated (NASDAQ: INSM) (before the open)
  • Seres Therapeutics Inc (NASDAQ: MCRB) (before the open)
  • Curis, Inc. (NASDAQ: CRIS) (before the open)
  • Acorda Therapeutics Inc (NASDAQ: ACOR) (before the open)
  • AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) (after the close)
  • Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the open)
  • Becton Dickinson and Co (NYSE: BDX) (before the open)
  • Arbutus Biopharma Corp (NASDAQ: ABUS) (after the close)
  • Emergent Biosolutions Inc (NYSE: EBS) (after the close)
  • T2 Biosystems Inc (NASDAQ: TTOO) (after the close)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the close)
  • Pacific Biosciences of California (NASDAQ: PACB) (after the close)
  • Nevro Corp (NYSE: NVRO) (after the close)
  • Cerus Corporation (NASDAQ: CERS) (after the close)
  • TESARO Inc (NASDAQ: TSRO) (after the close)
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the open)
  • Revance Therapeutics Inc (NASDAQ: RVNC) (after the close)
  • Pacira Pharmaceuticals Inc (NASDAQ: PCRX) (before the open)
  • Zoetis Inc (NYSE: ZTS) (before the open)
  • ResMed Inc. (NYSE: RMD)
  • Insulet Corporation (NASDAQ: PODD) (after the close)
  • Glaukos Corp (NYSE: GKOS) (after the close)
  • Repligen Corporation (NASDAQ: RGEN) (before the open)
  • Epizyme Inc (NASDAQ: EPZM) (before the open)
  • Aratana Therapeutics Inc (NASDAQ: PETX)

IPO

Bionano Genomics, an instrumentation company operating in the genome analysis space, is proposing to offer 3.35 million shares in an IPO, with the price range estimated between $8 and $10. The company intends to list its shares on the Nasdaq under the ticker symbol "BNGO."

Posted-In: Biotech Earnings News Health Care Previews FDA Top Stories Trading Ideas Best of Benzinga

 

Related Articles (ABBV + ABUS)

View Comments and Join the Discussion!

SEC Rule On Direxion Bitcoin ETFs Expected This Fall

Not The Sweetest Of News: Necco Shuts Down Factory